Biotech

All Articles

Amgen files first phase 3 win for $400M chronic eczema drug

.Amgen has actually shared (PDF) the 1st phase 3 information on its $400 thousand eczema drug, conne...

Biogen, UCB file period 3 lupus gain after neglecting earlier test

.Biogen and UCB's depend improving in to phase 3 on the back of a failed research tries to have sett...

Aptadir hopes new RNA inhibitors may reverse tricky cancers cells

.Italian biotech Aptadir Therapeutics has released along with the pledge that its pipe of preclinica...

Wave surfs DMD success to regulatory authorities' doors, sending out stockpile

.Surge Life Sciences has fulfilled its own target in a Duchenne muscular dystrophy (DMD) research, p...

Sanofi plucks brand-new CSO from in-stealth biotech

.After a handful of years in biotech, Mike Quigley, Ph.D., is going back to the pharma layer, occupy...

Achilles drips tissue treatment program, prepares for layoffs after overlooking 'business practicality' goals

.Achilles Rehabs has torn up its own technique. The British biotech is actually quiting working on i...

Aligos advertises phase 2 MASH succeed, lowering liver fat as much as 46%

.Aligos Rehabs is declaring a midstage gain in metabolic-dysfunction associated steatohepatitis (MAS...

Basilea credit ratings $268M BARDA funding for antifungals, prescription antibiotics

.Basilea Pharmaceutica's work developing brand-new antifungals has obtained a significant improvemen...

Capricor offers Europe rights to late-stage DMD treatment for $35M

.Having currently gathered up the USA legal rights to Capricor Rehabs' late-stage Duchenne muscle dy...

FDA junks adcomm for Applied's unusual ailment drug

.After dismissing the choice date for Applied Therapeutics' metabolic condition medicine govorestat,...